AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 84
- Registration Number
- NCT06106945
- Locations
- πͺπΈ
Research Site, Salamanca, Spain
A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99
- Registration Number
- NCT06103877
- Locations
- π©πͺ
Research Site, Berlin, Germany
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 625
- Registration Number
- NCT06103864
- Locations
- π»π³
Research Site, Vinh, Vietnam
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 239990
- Registration Number
- NCT06099067
- Locations
- πΈπͺ
Research Site, Gothenburg, Sweden
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
Recruiting
- Conditions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1070
- Registration Number
- NCT06099236
- Locations
- π¨π³
Research Site, Zhengzhou, China
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT06097728
- Locations
- π¬π§
Research Site, Taunton, United Kingdom
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06093542
- Locations
- π―π΅
Research Site, Sumida-ku, Japan
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1760
- Registration Number
- NCT06087835
- Locations
- π»π³
Research Site, Ho Chi Minh, Vietnam
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 94
- Registration Number
- NCT06084884
- Locations
- π°π·
Research Site, Seoul, Korea, Republic of
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT06079671
- Locations
- πΉπ·
Research Site, Karsiyaka, Turkey
Β© Copyright 2024. All Rights Reserved by MedPath